Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius Medical Care AG & Co. KGaA    FME   DE0005785802

FRESENIUS MEDICAL CARE AG & CO. KGAA

(FME)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care holds virtual General Meeting on August 27, 2020 - dividend proposal unchanged

share with twitter share with LinkedIn share with facebook
07/08/2020 | 03:05am EDT

DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): AGM/EGM
Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care holds virtual General Meeting on August 27, 2020 - dividend proposal unchanged

08.07.2020 / 09:03
The issuer is solely responsible for the content of this announcement.


Fresenius Medical Care, the world's leading provider of dialysis products and services, will hold its Annual General Meeting (AGM) on August 27, 2020 as a virtual event. Originally, the AGM was scheduled for May 19, 2020. It had to be postponed due to the coronavirus pandemic. As it is currently impossible to predict for how long the restrictions for large public events will be in effect, Fresenius Medical Care will use the option provided by the German legislator to hold a virtual event to safeguard the health of shareholders, employees and service providers.

The proposed dividend by the General Partner and the Supervisory Board remains unchanged at ?1.20 per share entitled to dividend.

Shareholders will be provided the possibility to follow the entire AGM on the internet. Fresenius Medical Care will include further details in the AGM invitation that is to be published in the Federal Gazette (Bundesanzeiger) and on the corporate website in July.

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,002 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 348,703 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company's website at www.freseniusmedicalcare.com.

Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.




Contact:
Dr. Dominik Heger
Head of Investor Relations, Strategic Development & Communications I EVP
dominik.heger@fmc-ag.com
P. +49 6172 609 2525


08.07.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Fresenius Medical Care AG & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
Phone: +49 (0) 6172- 609 2525
Fax: +49 (0) 6172- 609 2301
E-mail: ir@fmc-ag.com
Internet: www.freseniusmedicalcare.com
ISIN: DE0005785802
WKN: 578580
Indices: DAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; NYSE, Luxembourg Stock Exchange
EQS News ID: 1088691

 
End of News DGAP News Service

1088691  08.07.2020 

fncls.ssp?fn=show_t_gif&application_id=1088691&application_name=news&site_id=zonebourse
© EQS 2020

share with twitter share with LinkedIn share with facebook
All news about FRESENIUS MEDICAL CARE AG & CO. KGAA
10/23FRESENIUS SE : Receives a Buy rating from Goldman Sachs
MD
10/23FMC FRESENIUS MEDICAL CARE AG & CO K : Gets a Buy rating from Goldman Sachs
MD
10/22FRESENIUS SE : Credit Suisse reiterates its Neutral rating
MD
10/22FMC FRESENIUS MEDICAL CARE AG & CO K : Credit Suisse reaffirms its Neutral ratin..
MD
10/22FMC FRESENIUS MEDICAL CARE AG & CO K : Credit Suisse remains Neutral
MD
10/21FRESENIUS SE : Berenberg reiterates its Buy rating
MD
10/21Vifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuva t..
AQ
10/21FRESENIUS SE : Barclays reiterates its Buy rating
MD
10/21FMC FRESENIUS MEDICAL CARE AG & CO K : Receives a Buy rating from Barclays
MD
10/20FRESENIUS MEDICAL CARE : gets FDA approval for Biofine® PD solution bags
PU
More news
Financials (USD)
Sales 2020 21 505 M - -
Net income 2020 1 543 M - -
Net Debt 2020 14 311 M - -
P/E ratio 2020 15,4x
Yield 2020 1,74%
Capitalization 23 836 M 23 792 M -
EV / Sales 2020 1,77x
EV / Sales 2021 1,66x
Nbr of Employees 124 736
Free-Float 65,1%
Chart FRESENIUS MEDICAL CARE AG & CO. KGAA
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS MEDICAL CARE AG & CO. KGAA
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 99,54 $
Last Close Price 81,40 $
Spread / Highest target 41,4%
Spread / Average Target 22,3%
Spread / Lowest Target -1,84%
EPS Revisions
Managers
NameTitle
Rice Powell Chairman-Management Board
Dieter Schenk Chairman-Supervisory Board
Helen Giza Chief Financial Officer
Olaf Schermeier CEO-Global Research & Development
Franklin W. Maddux Global Chief Medical Officer